Option chain shows key data for Hikma Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hikma Pharmaceuticals.

Hikma Pharmaceuticals (OTC:HKMPF) Stock, Option Chain

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Biotech

Large Cap

News

Health Care

General

HKMPF

HKMPY

MCKPF

MNKTQ

TEVA

VTRS

Increase in production of Takeda&#39;s ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Shortage Relief: More Takeda&#39;s Vyvanse For ADHD On the Way As US Ramps Up Production

JAZZ

Legal

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. 

Methotrexate is an injected medication utilized to treat various cancers and autoimmune diseases like rheumatoid arthritis, as stated by the National Cancer Institute.

Drug Shortages in Focus: How FDA&#39;s Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape

HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc.

Comments

Hikma Pharmaceuticals

Hikma Pharmaceuticals (HKMPF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga